What is Amplified Sciences?
Amplified Sciences operates at the intersection of biotechnology and clinical diagnostics, focusing on the development of high-precision tests for early disease detection and risk stratification. The company's core innovation lies in its proprietary ultra-sensitive optical reporter platform, which facilitates a new class of multi-omics diagnostic tests. This technology is specifically engineered to address the complexities of challenging diseases, with a primary focus on pancreatic cancer through its flagship product, PanCystPro. By analyzing biomarker levels in pancreatic cyst fluid, the company provides clinicians with actionable data to improve patient outcomes and refine treatment strategies. The firm's market position is defined by its commitment to bridging the gap between laboratory innovation and clinical utility, ensuring that high-risk patients receive timely and accurate diagnostic insights.
How much funding has Amplified Sciences raised?
Amplified Sciences has raised a total of $2.4M across 3 funding rounds:
Debt
$15K
Angel/Seed
$1.8M
Debt
$550K
Debt (2021): $15K with participation from PPP
Angel/Seed (2021): $1.8M led by OCA Ventures, Purdue Ventures, and Elevate Ventures
Debt (2025): $550K, investors not publicly disclosed
Key Investors in Amplified Sciences
OCA Ventures
OCA Ventures is a venture capital firm dedicated to assisting entrepreneurs in the development of successful companies by providing essential support and resources to help startups thrive.
Elevate Ventures
Elevate Ventures is an active participant in cross-sector innovation, providing funding and guidance to early-stage companies with a focus on grit, creativity, and coachability.
Purdue Ventures
Purdue Ventures is an investment arm focused on supporting high-potential startups, often leveraging academic research and innovation to drive commercial success.
What's next for Amplified Sciences?
With the recent strategic investment, Amplified Sciences is well-positioned to transition from its current development phase toward broader clinical validation and market entry. The company is expected to prioritize the expansion of its multi-omics platform, potentially broadening its diagnostic scope beyond pancreatic health to address other high-burden conditions. Strategic focus will likely remain on clinical trial execution and regulatory milestones, which are essential for the widespread adoption of its diagnostic tools. As the company scales, the integration of its technology into standard clinical workflows will be a critical indicator of its long-term commercial viability. Investors and industry stakeholders will be monitoring the firm's ability to translate its technical breakthroughs into sustainable clinical impact, further solidifying its role in the evolving landscape of precision medicine.
See full Amplified Sciences company page
